Oruka Therapeutics, Inc. (ORKA) 2024年年度报告「NASDAQ」.pdf

1、 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 FORM 10-K (Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31,2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT O

2、F 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 000-22873 Oruka Therapeutics,Inc.(Exact name of Registrant as specified in its Charter)Delaware 36-3855489(State or other jurisdiction ofincorporation or organization)(I.R.S.Employer Identification No.)855 Oak Grove AvenueSuite 100Menlo

3、 Park,California 94025(Address of principal executive offices)(Zip Code)Registrants telephone number,including area code:(650)606-7910 Securities registered pursuant to Section 12(b)of the Act:Title of Each Class Trading Symbol(s)Name of Each Exchange on Which RegisteredCommon Stock,par value$0.001

4、per share ORKA The Nasdaq Global Market Securities registered pursuant to Section 12(g)of the Act:None Indicate by check mark if the Registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.YES NO Indicate by check mark if the Registrant is not required to file reports

5、 pursuant to Section 13 or 15(d)of the Act.YES NO Indicate by check mark whether the Registrant:(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934during the preceding 12 months(or for such shorter period that the Registrant was required to file

6、 such reports),and(2)has been subject to such filingrequirements for the past 90 days.YES NO Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T(232.405 of this chapter)during the preced